Trends in the Treatment of Ductal Carcinoma In Situ of the Breast

Background: An increase in incidence of ductal carcinoma in situ (DCIS) of the breast has been documented, and concerns regarding overly aggressive treatment have been raised. This study was designed to evaluate the use of surgery and radiation therapy in treating DCIS. Methods: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results database to assess treatment of patients with DCIS with no evidence of microinvasion who were diagnosed from January 1, 1992, through December 31, 1999. We assessed the rates of mastectomy, breast reconstruction, radiation therapy after lumpectomy, and axillary dissection. Associations were analyzed by logistic regression. Results: During the study period, 25 206 patients met selection criteria. The incidence of DCIS dramatically increased with time; however, the incidence of comedo lesions did not change. The rate of mastectomy decreased from 43% in 1992 to 28% in 1999, after controlling for age, race, tumor size, comedo histology, and geographic location. However, because of the increase in the diagnosis of DCIS, the age-adjusted incidence of mastectomy for DCIS in the population did not change (7.8 per 100 000 women in 1992 and 1999). Almost half the patients undergoing lumpectomy did not undergo radiation therapy (55% in 1992 and 46% in 1999); in those with comedo histology, 33% did not undergo radiation therapy after lumpectomy, even in 1999. Overall, patients were less likely to have axillary dissection over time (34% in 1992 versus 15% in 1999), yet the rate of axillary dissection was still high (30%) in patients undergoing mastectomy in 1999. Large, statistically and clinically significant variation by geographic location was found in treatment. Conclusions: Treatment of DCIS changed in a clinically significant fashion between 1992 and 1999. Throughout this study, many patients were found to undergo aggressive surgical therapy, including mastectomy and axillary dissection, whereas others appeared to be undertreated, e.g., not receiving radiation therapy after lumpectomy, even in the presence of adverse histologic features. Variation in demographic and geographic factors indicates that at least some of these treatment differences reflect individual and institutional practice patterns that may be modifiable.

[1]  B. Cady New diagnostic, staging, and therapeutic aspects of early breast cancer , 1990, Cancer.

[2]  S. Schnitt,et al.  Ductal carcinoma in situ (intraductal carcinoma) of the breast. , 1988, The New England journal of medicine.

[3]  S. Edge,et al.  Patterns of radiation use as a component of breast conservation therapy for noninvasive and invasive breast cancers in united states national comprehensive cancer network (nccn) centers , 2003 .

[4]  J. Peterse,et al.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 , 2000, The Lancet.

[5]  J. Gurwitz,et al.  Use of breast-conserving surgery for treatment of stage I and stage II breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Cody,et al.  Point: sentinel lymph node biopsy is indicated for patients with DCIS. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  R. Cote,et al.  Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies1 , 2001 .

[8]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[9]  S. Schnitt,et al.  Treatment selection in ductal carcinoma in situ. , 2000, JAMA.

[10]  P. Lantz,et al.  Correlates of surgical treatment type for women with noninvasive and invasive breast cancer. , 2001, Journal of women's health & gender-based medicine.

[11]  G. Sakorafas,et al.  Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. , 2000, Cancer treatment reviews.

[12]  J. Houghton Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[13]  G. Murphy,et al.  Noninvasive Breast Carcinoma: Results of a National Survey by the American College of Surgeons , 1980, Annals of surgery.

[14]  F. Gilliland,et al.  Trends in incidence and treatment for ductal carcinoma in situ in Hispanic, American Indian, and non‐Hispanic white women in New Mexico, 1973–1994 , 1999, Cancer.

[15]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[16]  J. Cawson,et al.  Axillary dissection and ductal carcinoma in situ of the breast: a change in practice. , 2000, The Australian and New Zealand journal of surgery.

[17]  Roy A Jensen,et al.  Ductal Carcinoma In Situ of the Breast: Impact of Pathology on Therapeutic Decisions , 2003, The American journal of surgical pathology.

[18]  S. Edge,et al.  Counterpoint: sentinel lymph node biopsy is not indicated for ductal carcinoma in situ. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[20]  V. Shavers,et al.  Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35 , 2003, Cancer.

[21]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[22]  K I Bland,et al.  The National Cancer Data Base 10‐year survey of breast carcinoma treatment at hospitals in the United States , 1998, Cancer.

[23]  M. Silverstein,et al.  Sentinel Node Biopsy for Patients With DCIS: A Dangerous and Unwarranted Direction , 2001, Annals of Surgical Oncology.

[24]  D. Winchester,et al.  National treatment trends for ductal carcinoma in situ of the breast. , 1997, Archives of surgery.

[25]  A. Legorreta,et al.  Axillary node dissection in ductal carcinoma in situ. , 1998, American journal of clinical oncology.

[26]  E. Fisher,et al.  Avoiding the unintended consequences of growth in medical care: how might more be worse? , 1999, JAMA.

[27]  N. Wolmark,et al.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. , 2001, Seminars in oncology.

[28]  S. Singletary,et al.  Standard for the Management of Ductal Carcinoma In Situ of the Breast (DCIS) , 2002, CA: a cancer journal for clinicians.

[29]  J. Pierce,et al.  Regional differences in the incidence and treatment of carcinoma in situ of the breast. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  K. Kerlikowske,et al.  Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. , 2000, Archives of internal medicine.

[31]  Katherine L Kahn,et al.  Validity of cancer registry data for measuring the quality of breast cancer care. , 2002, Journal of the National Cancer Institute.

[32]  D. Winchester,et al.  Treatment trends for ductal carcinoma in situ of the breast , 1995, Annals of Surgical Oncology.

[33]  M. Moore,et al.  Treatment of ductal carcinoma in situ of the breast. , 1991, Seminars in surgical oncology.

[34]  G. Schwartz The Current Treatment of Ductal Carcinoma in Situ , 2001, The breast journal.